The landscape of gastrointestinal oncology is currently witnessing a paradigm shift. As our understanding of molecular biology and surgical precision evolves, so too does the imperative to address some of the most aggressive malignancies in the human body: biliary tract cancers. In a concerted effort to synthesize global clinical advancements, Expert Review of Gastroenterology & Hepatology—a flagship journal under the Taylor & Francis imprint—has officially launched a call for submissions for a specialized Article Collection focused on "Biliary Cancer Prevention and Treatment."
This initiative aims to serve as a comprehensive repository for the latest breakthroughs in the diagnosis, management, and long-term care of patients battling cholangiocarcinoma and gallbladder cancer. By bridging the gap between translational laboratory research and bedside clinical application, the collection seeks to provide a roadmap for the future of hepatobiliary oncology.
Main Facts: The Scope of the Initiative
The upcoming collection, hosted by Expert Review of Gastroenterology & Hepatology, is designed to be a multidisciplinary forum. It invites contributions from a diverse array of experts, including medical oncologists, hepatobiliary surgeons, radiologists, and translational researchers.
Core Pillars of the Collection
The editorial board is particularly interested in submissions that address the following critical areas:
- Early Detection and Molecular Profiling: As biliary cancers are often diagnosed at advanced stages, there is an urgent need for research regarding novel biomarkers that allow for earlier intervention.
- Surgical Innovations: Papers detailing advancements in minimally invasive surgical techniques and complex liver resection protocols are highly encouraged.
- Systemic Therapies: The collection will highlight the latest in immunotherapy, targeted molecular agents, and combination chemotherapies that are currently redefining the standard of care.
- Evidence-Based Management: Beyond surgical and systemic treatments, the collection will focus on comprehensive care strategies that prioritize patient quality of life and long-term outcomes.
Authors are invited to submit various formats, including Reviews, Original Research, Drug Profiles, and concise Editorials. This versatility ensures that the collection will serve both as a primary research reference and as a high-level review of current clinical practice.
Chronology: The Evolution of Biliary Cancer Management
To understand the necessity of this collection, one must examine the rapid evolution of hepatobiliary oncology over the last decade.
The Last Decade (2014–2024)
- 2014–2017: The Era of Standard Chemotherapy. For many years, the treatment of advanced cholangiocarcinoma relied heavily on gemcitabine-based combinations, with limited survival benefits and few targeted options.
- 2018–2020: The Genomic Revolution. The emergence of high-throughput sequencing allowed for the identification of actionable mutations, most notably in FGFR2 fusions and IDH1 mutations. This fundamentally altered the treatment algorithm for a subset of patients.
- 2021–2023: The Advent of Immunotherapy. The integration of immune checkpoint inhibitors into first-line treatment protocols marked a historic milestone, finally providing a long-awaited survival benefit for a broader population of patients.
- 2024–Present: The Current Call. The launch of the Expert Review of Gastroenterology & Hepatology collection represents the next phase: the consolidation of these diverse findings into a unified, evidence-based clinical framework.
Supporting Data: The Clinical Imperative
Biliary tract cancers (BTCs), while relatively rare in global populations, represent a significant clinical challenge due to their late-stage presentation and inherent resistance to traditional cytotoxic therapies.
Epidemiological Context
Recent epidemiological data indicate that the incidence of intrahepatic cholangiocarcinoma has been steadily rising globally. Unlike hepatocellular carcinoma, which is often tied to viral hepatitis, the etiology of biliary malignancies is multifactorial, involving chronic inflammation, primary sclerosing cholangitis, and specific environmental factors.
The Need for Targeted Innovation
Data from recent clinical trials suggest that "one-size-fits-all" chemotherapy is becoming obsolete. For instance, the use of targeted therapies for patients harboring specific genetic alterations has shown progression-free survival rates that significantly outperform historical benchmarks. However, the hurdle remains the rapid development of resistance and the high cost and complexity of molecular profiling in community settings.
This collection seeks to provide the data-driven insights necessary to help clinicians navigate these choices. By curating peer-reviewed analyses of these targeted therapies, the journal aims to shorten the time between a laboratory discovery and the implementation of a new standard of care in the clinic.
Official Responses and Editorial Vision
The editorial team at Taylor & Francis has emphasized that this project is not merely an academic exercise, but a necessary response to a changing clinical environment.
"The landscape of biliary cancer is shifting faster than many clinical guidelines can keep up with," says the commissioning team. "By providing a dedicated space for this research, we are ensuring that clinicians—who are often overwhelmed by the volume of new data—have a vetted, centralized resource to inform their patient care decisions."
Guidance for Prospective Contributors
The journal has streamlined the submission process to encourage participation from researchers worldwide. Prospective authors are encouraged to engage with the Commissioning Editor, Olivia Clovis-Corbett, to discuss potential topics, abstract alignment, and submission timelines.
The editorial policy remains rigorous: while the collection is broad in scope, all submissions will undergo the same stringent peer-review process that defines the reputation of Expert Review of Gastroenterology & Hepatology. This ensures that the final collection remains a trusted resource for the global medical community.
Implications: The Future of Patient Care
The implications of this initiative extend far beyond the pages of a journal. By fostering this collaborative discourse, the medical community can expect several key outcomes:
1. Standardization of Care
Disparities in the treatment of biliary cancers often exist between academic centers of excellence and community-based practices. This collection serves as a bridge, disseminating the "best-in-class" practices to a wider audience, thereby potentially reducing regional disparities in patient outcomes.
2. Acceleration of Translational Research
By grouping original research with drug profiles and clinical reviews, the collection facilitates "bench-to-bedside" connectivity. Researchers working in molecular biology will be able to see how their work aligns with current clinical challenges, while clinicians will gain a deeper understanding of the biological mechanisms behind the drugs they prescribe.
3. Patient-Centric Innovation
Ultimately, the goal of this collection is to improve survival rates and quality of life for patients. The focus on both systemic therapies and management strategies underscores a commitment to the "whole patient"—recognizing that treating aggressive malignancies requires not just potent drugs, but a comprehensive, multidisciplinary approach to symptom management, palliative care, and psychological support.
4. A Dynamic Resource
Unlike static textbooks, this Article Collection is a living, digital resource. It reflects the fluid, fast-paced nature of modern oncology. As new findings emerge throughout the submission window, the collection will grow, providing a real-time snapshot of the current state of the art.
Conclusion: A Call to Action
The call for papers for the Expert Review of Gastroenterology & Hepatology collection is a clarion call to the international hepatobiliary community. It is an invitation to contribute to a body of work that will inevitably influence clinical decision-making, patient outcomes, and the future research agenda for years to come.
For researchers and clinicians working in the field of cholangiocarcinoma and gallbladder cancer, this is an opportunity to share insights that could redefine treatment pathways. Whether through the lens of a groundbreaking clinical trial, a nuanced review of surgical complications, or a detailed drug profile, your contribution will play a vital role in shaping the next chapter of hepatobiliary care.
Interested parties are encouraged to:
- Review the scope: Visit the official Taylor & Francis submission page to read the full scope and submission guidelines.
- Engage with the Editorial Team: Contact Olivia Clovis-Corbett at [email protected] to discuss your proposed submission.
- Participate: Join a global cohort of experts dedicated to overcoming one of the most significant challenges in modern gastroenterology.
As the boundaries of what is possible in cancer treatment continue to expand, initiatives such as this remain the bedrock of progress. Through the rigorous exchange of ideas, the medical community moves one step closer to transforming biliary cancer from an aggressive, life-limiting diagnosis into a manageable condition—a future that is being built, one article at a time.
About the Author
